Sarepta Therapeutics (SRPT) to Post Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sarepta Therapeutics to post earnings of $0.2173 per share and revenue of $366.3920 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating the consensus estimate of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.42) earnings per share. On average, analysts expect Sarepta Therapeutics to post $4 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $14.86 on Monday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The company’s fifty day simple moving average is $16.99 and its 200 day simple moving average is $18.67. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -15.48, a PEG ratio of 0.16 and a beta of 0.24.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $25,000. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP raised its stake in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SRPT shares. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and a consensus price target of $24.72.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.